Stephen B. Hanauer
0000-0002-3268-932X
Publication & Citation Trends
Publications
766 total
Tu1710 ADDITIONAL RISANKIZUMAB TREATMENT IS EFFECTIVE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO DID NOT ACHIEVE CDAI CLINICAL RESPONSE WITH THE INITIAL 12-WEEK INDUCTION TREATMENT: RESULTS FROM THE ADVANCE, MOTIVATE, AND FORTIFY STUDIES
Cited by 0
Semantic Scholar
Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn’s disease (VOLTAIRE-CD): a multicenter, randomized, double-blind, phase 3 trial
Cited by 0
Semantic Scholar
Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn's disease. OA
Cited by 0
Semantic Scholar
Editorial: safety and efficacy of infliximab and corticosteroids in checkpoint inhibitor‐induced colitis OA
Cited by 1
Semantic Scholar
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Cited by 195
Semantic Scholar
Atovaquone attenuates experimental colitis by reducing neutrophil infiltration of colonic mucosa OA
Cited by 7
Semantic Scholar
IB D ADVANCES IN IBD Section
Cited by 0
Semantic Scholar
OP02 Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn’s Disease: The SEAVUE study OA
Cited by 39
Semantic Scholar
Research Topics
Inflammatory Bowel Disease
(518)
Microscopic Colitis
(348)
Eosinophilic Esophagitis
(102)
Immunodeficiency and Autoimmune Disorders
(66)
Autoimmune and Inflammatory Disorders
(57)
Affiliations
Semmelweis University
Northwestern University
Tulane University
University of Copenhagen
Western University